AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04110262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dietary sodium intake
Description: Fourteen day feeding period of low dietary sodium (2300 mg/day)
Study NCT05249192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate urinary catheter removal
Description: Urinary catheter removal immediately after the end of the surgical procedure before exiting the operating room.
Study NCT05249192 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Early urinary catheter removal
Description: urinary catheter removal on the first postoperative day (6 a.m)
Study NCT04580225 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four-Corner Arthrodesis
Description: Participants in Group A will receive a four-corner arthrodesis (fusion of the capitate, hamate, lunate, and triquetrum) with excision of the scaphoid.
Study NCT04580225 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Three-Corner or Capitolunate Arthrodesis with Triquetral Excision
Description: Participants in Group B will receive a three-corner arthrodesis (fusion of the capitate, hamate, and lunate) or capitolunate arthrodesis (fusion of the capitate and lunate) with excision of the scaphoid and triquetrum.
Study NCT05471479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Activated Charcoal
Description: Activated charcoal
Study NCT05471479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No activated charcoal
Description: No activated charcoal
Study NCT04751396 — intervention group
Intervention type: OTHER
Intervention: Best Practice
Description: Receive standard educational information
Study NCT06335758 — intervention group
Intervention type: DEVICE
Intervention: Use of ReX to dispense and monitor solid oral medication therapy.
Description: ReX Remote Digital Nurse comprising hand-held dispenser, disposable drug cartridge and web application (ReX Treatment Manager).
Study NCT04751396 — intervention group
Intervention type: OTHER
Intervention: Educational Intervention
Description: Navigate educational tool
Study NCT04751396 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Participate in interview
Study NCT05518513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: adductor canal block with 0.25% bupivacaine
Study NCT05518513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: adductor canal block with 0.25% bupivacaine
Study NCT05049629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lacrimera
Description: A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
Study NCT05049629 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hylo-Vision
Description: Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine)
Study NCT04683497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Intraoperative Ultrasound
Description: Intraoperative ultrasound with the administration of a contrast agent I.V.
Study NCT06233955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level laser therapy
Description: is a non-invasive light source treatment that generates a single wavelength of light. It emits no heat, sound, or vibration. It is also called photobiology or bio-stimulation
Study NCT06233955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland mobilization technique
Description: is a process of examination; assessment and treatment of musculoskeletal disorders by manipulative physiotherapy where a chain of oscillatory joint mobilization grades based on the pathological limit of tissue are used
Study NCT04751396 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT04751396 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study NCT05926804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: 14 days of Lansoprazole (30 mg BID) (days 1-14)
Study NCT05926804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 7 days of Amoxicillin (1000 mg BID) (days 1-7)
Study NCT05926804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 7 days of Clarithromycin (500 mg BID) (days 8-14)
Study NCT05926804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 7 days of Metronidazole (500 mg BID) (days 8-14)
Study NCT04700111 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DOT Pattern
Description: DOT Pattern Spectacle Lens
Study NCT04700111 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Spectacles
Description: Control lens
Study NCT05355402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olezarsen
Description: Olezarsen will be administered by SC injection.
Study NCT05355402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Olezarsen-matching placebo will be administered once every 4 weeks by SC injection for up to 49 weeks.
Study NCT05506904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extubation Advisor
Description: Participants undergoing a Spontaneous Breathing Trial (SBT) to assess readiness for extubation will be connected to a portable monitor displaying ECG, capnography, and other waveforms. This monitor will also be connected to a laptop containing the Extubation Advisor (EA) software. During the SBT, relevant patient information will be entered into the EA application and the EA application will record waveform data. When the SBT is complete, the EA application will analyze the waveform and patient data to generate a score summarizing the risk of extubation failure. A report will be generated and provided to the respiratory therapist and attending physician to help determine whether to proceed with extubation or not. The clinical outcome case report form will be completed at the time of hospital discharge.
Study NCT04793776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manage Emotions to Reduce Aggression
Description: MERA begins with education about the adaptive nature of emotions, how childhood and military experiences can influence emotion regulation, and how combat requires different emotion regulation strategies than most civilian environments. MERA use modeling and practice with feedback to teach cognitive-behavioral and acceptance-based emotion regulation skills.
Study NCT04793776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Psychotherapy
Description: PCT will serve as the comparison group. PCT assists Veterans in understanding and coping with current difficulties, such as aggression, but does not provide systematic training in emotion regulation skills.
Study NCT05616130 — intervention group
Intervention type: OTHER
Intervention: Data Collection
Description: Researcher will collect data from subject's medical records: information regarding your medical history, trauma injury, heart rate, blood pressure, temperature (vital signs), use of antibiotics (medications used to treat infection) and other medications, development of infection, and treatment results will be recorded and kept with your research records. Demographic information (such as name, address, phone number, gender, race, height and weight, age and birth date), medical record notes (including but not limited to history and physical exam notes, progress notes, consultation reports, laboratory test results, operative reports, information relating to acquired immunodeficiency virus (HIV) infection, radiologic (x-ray studies) results, and blood samples)
Study NCT05616130 — intervention group
Intervention type: PROCEDURE
Intervention: Bone marrow collection and blood collection
Description: At time of scheduled surgery, researcher will collect a 20ml (approximately 4 teaspoons) sample of bone marrow while you are in the operating room receiving surgery for your orthopedic (bone) injuries or elective hip repair. Blood collection will occur at time of surgery, day 14 on study or discharge from hospital and at 3 and 6 months. Up to 58 ml (about 4 tablespoons) sample of blood will be collected from an existing intravenous line or peripheral needle stick.
Study NCT05616130 — intervention group
Intervention type: OTHER
Intervention: Serial interviews to complete surveys and questionnaires
Description: Participants will be asked to complete questionnaires and surveys that assess your health, quality of life, daily living activities, and mobility. These activities occur at enrollment, day 14 in hospital or discharge, and at the 3, 6, and 12-month visits.
Study NCT05616130 — intervention group
Intervention type: OTHER
Intervention: Telephone follow up call
Description: The study team will contact you at 12 months to complete a telephone interview to learn about your health and well being.
Study NCT05639933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HT-001 2% Topical Gel
Description: Topical gel, 2% active
Study NCT05639933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-001 2% Topical Gel
Description: Topical gel, 2% active
Study NCT05639933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-001 1% Topical Gel
Description: Topical gel, 1% active
Study NCT05639933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-001 0.5% Topical Gel
Description: Topical gel, 0.5% active
Study NCT05639933 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HT-001 Placebo
Description: Topical gel, vehicle gel
Study NCT06448286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemical Exchange Saturation Transfer Magnetic Resonance Imaging
Description: Undergo CEST MRI
Study NCT06448286 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo contrast-enhanced MRI
Study NCT06448286 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06448286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06448286 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy
Study NCT06448286 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo standard of care radiation therapy
Study NCT06448286 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Procedure
Description: Undergo surgical resection
Study NCT06448286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo surgical resection
Study NCT06448286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given PO
Study NCT05533151 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training
Description: All patients will be initially educated by a physiotherapist and instructed to independently perform the home exercise program including respiratory muscle training. The training will be performed using the Airofit PRO device. This breathing training on a suitable resistance will be performed twice a day for 6 weeks. The intervention will be conducted under a researcher's supervision via smartphone App.
Study NCT06439394 — intervention group
Intervention type: DRUG
Intervention: Optive MEGA-3 (OM3)
Description: Eye Drops
Study NCT06673238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-722
Description: Oral Capsule
Study NCT05826548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telerehabilitation group
Description: Patients will undergo the experimental intervention for 1 hour/day, for 5 days, for 4 weeks.
Study NCT05826548 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventioanl treatment group
Description: Patients will undergo the control intervention for 1 hour/day, for 5 days, for 4 weeks.
Study NCT06448286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT06511063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil/emtricitabine
Description: Participants will take Truvada (TDF/FTC, tenofovir disoproxil/emtricitabine) for 90 days.
Study NCT06511063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selzentry
Description: Participants will take Selzentry for 90 days.
Study NCT06511063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo.
Study NCT05398003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the WAVEWRITER ALPHA ™ device
Description: The 12 patients will be implanted by the WAVEWRITER ALPHA ™ device. Then, the order of the three stimulation modes will be randomly selected and will be composed of 5 modalities:~* tonic stimulation LF: In tonic mode, the electrical stimulation of the sensory fibres of the posterior cords of the spinal cord induces local paresthesias~* high frequency stimulation (1000 Hz) High Frequency.~* stimulation in bursts (or Burst)
Study NCT03624400 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT-I
Description: The adapted Internet-based CBT-I for adolescents with ASD includes sleep hygiene, restriction of time in bed, stimulus control, cognitive therapy, and relaxation techniques. The treatment consists of 8 weekly modules and each module consists of several website pages that will be presented in a fixed order, with preprogrammed modules containing information, interactive questionnaires, descriptions of exercises and movies.
Study NCT03624400 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based psychoeducation
Description: Internet-based psychoeducation contains information about ASD, sleep difficulties and aspects of sleep hygiene. The intervention takes place in 8 weeks modules.
Study NCT06218069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sasanlimab
Description: 6 mL of the study drug will be administered subcutaneous injection in the abdominal fat fold. If SC injections in the abdominal location are not possible, SC injections can be administered in a distributed manner in the thighs. SC injections in the upper extremities (eg, deltoid, upper and lower arm) are not permitted. Any observed abnormality at the injection site (e.g. erythema, induration, ecchymosis, injection site pain, injection site pruritus) will be monitored and judged by the investigator to determine whether a corresponding AE should be reported.
Study NCT06218069 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: non-ablative radiotherapy
Description: Patients will receive a total dose of 24Gy irradiation to the tumor, fractionated in 3 doses of 8Gy, on three consecutive days and starting on the day of first sasanlimab administration.
Study NCT06218069 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: [89Zr]Zr-crefmirlimab berdoxam
Description: Prior to sasanlimab injection and prior to surgery, \[89Zr\]Zr-crefmirlimab berdoxam (1.5 mg protein dose labelled with activity dose 37 MBq Zirconium-89) will be administered via an intravenous catheter. After 21-27 hours after injection patient will undergo a whole-body PETscan te detect CD8+ T-cell infiltration.
Study NCT05192122 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Discontinue maintenance therapy SOC
Description: Continue maintenance therapy SOC
Study NCT04529044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05607797 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Epidemiological study
Description: Sociodemographic data collection, treatments collection, physical assessment, clinical examination and physical and biological measurements, biological evaluation (blood and urine samples), CKD-specific clinical features collection, gout-specific clinical features collection, clinical characteristics specific to chronic diseases, questionnaires (Health Assessment Questionnaire (HAQ-II), EuroQol (EQ)-5D-5L, joint pain, state of health, diet and physical activity, access to care, addictions, pain scale (EVA), personal and family history)
Study NCT05607797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epidemiological study
Description: Sociodemographic data collection, treatments collection, physical assessment, clinical examination and physical and biological measurements, biological evaluation (blood and urine samples), CKD-specific clinical features collection, gout-specific clinical features collection, clinical characteristics specific to chronic diseases, questionnaires (Health Assessment Questionnaire (HAQ-II), EuroQol (EQ)-5D-5L, joint pain, state of health, diet and physical activity, access to care, addictions, pain scale (EVA), personal and family history)
Study NCT05578690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: An initial 8 weeks of low-calorie diet including meal replacements (total of 800 kcal/day) will be initiated with the objective to lose at least 10% of initial body weight. From week 8 until week 12, an individual food-reintroduction plan will take place with partial meal product substitution. At week 12 and until pregnancy dieticians will ensure sustained compliance with diet aligned with the general recommendations for women seeking pregnancy (low-fat diet, rich in protein and carbohydrates and in some individuals slightly carbohydrate-reduced diet (prediabetes or family disposition to diabetes) with focus on carbohydrate quality (more fiber and whole grain). Consultations with a dietician for mapping diet and eating patterns and regular follow-up with a dietitian to maintain diet changes and modify diets if needed.
Study NCT05578690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After an initial 8-week ramp-up phase (during the initial low-calorie diet), the women will be encouraged to attend supervised exercise sessions on the study location (combination of vigorous-intensity, interval-based indoor cycling, and circuit training) twice weekly and to perform additional moderate-to vigorous-intensity exercise to obtain at least 150 min per week of moderate-intensity or 75 min per week of vigorous-intensity physical activity or a combination. The plan will include individual exercise and/or group exercise. Exercise watches with heart-rate monitors will be worn at each exercise session to determine whether the requirement regarding weekly time spent at moderate or vigorous intensity will be met. Regular follow-up with the women to maintain exercise changes and modify the exercise plan if needed.
Study NCT05578690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentorship
Description: Women are offered an individualized plan to successfully fulfil the multifactorial lifestyle intervention and the women will be offered both individual and/or group sessions with a mentor. After 8 weeks of the intervention, the women will be invited to another meeting where the choice of mentor will be evaluated, and the women will be offered to join a pre-parents-group. Group sessions will include conversational sessions, cooking classes and exercise classes with focus on changing lifestyle and maintaining a healthy lifestyle change. At the time of pregnancy groups will be reconsidered and the women will be offered participation in pregnancy-groups.
Study NCT04529044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT04529044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT04529044 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-DOTATATE
Description: Receive 68Ga
Study NCT04529044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given IV
Study NCT04900363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK112
Description: Subjects receive AK112 intravenously.
Study NCT04950543 — intervention group
Intervention type: BEHAVIORAL
Intervention: Meditation
Description: An online survey will be offered to participants who have enrolled in a 21-day meditation online course. The survey will be conducted using mobile website technology before and after the online course and additionally after 3 and 6 months.
Study NCT04529044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05610644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isocaloric, isonitrogenous meals
Description: Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.
Study NCT05610644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isocaloric, isonitrogenous meals
Description: Participants will eat prepared study meals for 3 days that have either the RDA of protein per day or twice the RDA of protein per day.
Study NCT05977998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given by IP (Intraperitoneal injection)
Study NCT05977998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given by IV (vein)
Study NCT05977998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Given by IV (vein)
Study NCT05977998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Given by IV (vein)
Study NCT04794699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE397
Description: IDE397 dosed orally